21 results
424B5
VERV
Verve Therapeutics Inc
29 Nov 23
Prospectus supplement for primary offering
4:47pm
in the patient dosed in the 0.6 mg/kg cohort was classified as a Grade 3 event. All infusion reactions and liver transaminase elevations resolved … a partnership or other entity or arrangement classified as a partnership for U.S. federal income tax purposes) of our common stock who is not for U.S
424B5
VERV
Verve Therapeutics Inc
28 Nov 23
Prospectus supplement for primary offering
4:25pm
in the patient dosed in the 0.6 mg/kg cohort was classified as a Grade 3 event. All infusion reactions and liver transaminase elevations resolved … a partnership or other entity or arrangement classified as a partnership for U.S. federal income tax purposes) of our common stock who is not for U.S
8-K
VERV
Verve Therapeutics Inc
13 Nov 23
Other Events
6:34am
bilirubin levels below the upper limit of normal. The increase in liver transaminases in the patient dosed in the 0.6 mg/kg cohort was classified
424B5
ivgcik1
21 Jul 22
Prospectus supplement for primary offering
4:43pm
424B5
e30hy0 3cko4589eku0
20 Jul 22
Prospectus supplement for primary offering
4:22pm
10-K
2blxa207agiq789h
14 Mar 22
Annual report
7:04am
10-Q
su0ek6
12 Aug 21
Quarterly report
8:53am
8-K
9vy39jqwgnw5x309d
21 Jun 21
Amendments to Articles of Incorporation or Bylaws
5:06pm
424B4
tm9080g4w3f067ed
17 Jun 21
Prospectus supplement with pricing info
4:50pm
S-1/A
pthjmy34yz9 k1ww
14 Jun 21
IPO registration (amended)
6:15am
S-1
25ugo4ms8k4sx
28 May 21
IPO registration
4:04pm